Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs

OU Min; WANG Yaqin; ZHU Zhimin; ZHANG Fangfang; ZHU Qiongni

doi:10.6039/j.issn.1001-0408.2025.18.14

您当前的位置：

首页 >

文章列表页 >

Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs

更新时间：2025-09-25

- Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs
- ZHONGGUO YAOFANG Vol. 36, Issue 18, Pages: 2297-2300(2025)
- 作者机构：
  
  1.上海交通大学医学院附属瑞金医院药剂科，上海　200025
  2.河南省人民医院药剂科，郑州　450003
  3.上海市第八人民医院药学部，上海　200235
  4.青海油田医院药剂科，甘肃敦煌　736202
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.18.14
  CLC： R979.1
- Received：20 March 2025，
  
  Revised：2025-08-14，
  
  Accepted：14 August 2025，
  
  Published：30 September 2025
- 稿件说明：
移动端阅览
欧敏,王亚琴,朱志敏,等.贝伐珠单抗生物类似药与原研生物药的临床转换模式及转换原因分析[J].中国药房,2025,36(18):2297-2300.

OU Min,WANG Yaqin,ZHU Zhimin,et al.Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs[J].ZHONGGUO YAOFANG,2025,36(18):2297-2300.
欧敏,王亚琴,朱志敏,等.贝伐珠单抗生物类似药与原研生物药的临床转换模式及转换原因分析[J].中国药房,2025,36(18):2297-2300. DOI： 10.6039/j.issn.1001-0408.2025.18.14.

OU Min,WANG Yaqin,ZHU Zhimin,et al.Clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs[J].ZHONGGUO YAOFANG,2025,36(18):2297-2300. DOI： 10.6039/j.issn.1001-0408.2025.18.14.

摘要

目的

分析贝伐珠单抗生物类似药与原研生物药的临床转换模式及转换原因。

方法

回顾性收集2018年1月1日至2023年12月31日在上海交通大学医学院附属瑞金医院接受贝伐珠单抗治疗的1 175例肿瘤患者资料，按用药类型分为原研生物药组（

＝250）和生物类似药组（

＝925）。比较两组患者的转换率、转换类型及转换原因。

结果

两组患者的转换率、转换类型、转换次数比较，差异均无统计学意义（

＞0.05），转换类型均以单次、单向转换为主。生物类似药组患者因不良事件转换的比例显著高于原研生物药组，因治疗成本转换的比例显著低于原研生物药组（

＜0.05）；两组患者因疗效和药物可及性转换的比例比较，差异均无统计学意义（

＞0.05）。

结论

贝伐珠单抗生物类似药与原研生物药均以单次、单向转换为主；治疗成本和药物可及性是原研生物药使用者转换的主要原因，药物可及性和不良事件是生物类似药使用者转换的主要原因。

Abstract

OBJECTIVE

To analyze clinical switching patterns and reasons between bevacizumab biosimilar and originator drugs.

METHODS

The data were collected from 1 175 cancer patients treated with bevacizumab at Ruijin Hospital， Shanghai Jiao Tong University School of Medicine from January 1， 2018， to December 31， 2023. The patients were divided into originator group （

＝250） and biosimilar group （

＝925）. The switching rate， switching type and reasons of the two groups were compared.

RESULTS

There were no statistically significant differences in the switching rate， switching types， and the number of switches between the two groups （

＞0.05）. Single， one-way switches were the switching type in both groups. The proportion of patients in the biosimilar group who switched due to adverse events was significantly higher than originator group， while the proportion of patients who switched due to treatment costs was significantly lower than originator group （

＜0.05）. There were no statistically significant differences in the proportions of patients who switched due to efficacy and drug accessibility between the two groups （

＞0.05）.

CONCLUSIONS

The switching between bevacizumab biosimilar and the originator drugs mainly involves single， one-way switches. Treatment costs and drug accessibility are the main factors for the switches among users of originator drugs， while drug accessibility and adverse events are the main factors for the switches among users of biosimilar.

关键词

Keywords

references

SHERIDAN M ， MASSICH M ， ASHOURIAN N . Biosimilars：from production to patient [J ] . J Infus Nurs ， 2024 ， 47 （ 1 ）： 19 - 29 .

GALVAO T F ， LIVINALLI A ， LOPES L C ， et al . Biosimilar monoclonal antibodies for cancer treatment in adults [J ] . Cochrane Database Syst Rev ， 2024 ， 11 （ 11 ）： CD013539 .

张敏，金婉霞 . 多款国产生物类似药产品成功“出海” 其他国内药企积极布局 [N ] . 证券日报， 2024-05-08 （ B02 ）.

KURKI P ， BARRY S ， BOURGES I ， et al . Safety，immunogenicity and interchangeability of biosimilar mono-clonal antibodies and fusion proteins：a regulatory perspec-tive [J ] . Drugs ， 2021 ， 81 （ 16 ）： 1881 - 1896 .

BENNETT C L ， SCHOEN M W ， HOQUE S ， et al . Improving oncology biosimilar launches in the EU，the USA，and Japan：an updated policy review from the southern network on adverse reactions [J ] . Lancet Oncol ， 2020 ， 21 （ 12 ）： e575 - e588 .

MACHADO S ， CRUZ A ， FERREIRA P L ， et al . Policy measures and instruments used in European countries to increase biosimilar uptake：a systematic review [J ] . Front Public Health ， 2024 ， 12 ： 1263472 .

CHEN B ， NAGAI S ， ARMITAGE J O ， et al . Regulatory and clinical experiences with biosimilar filgrastim in the U.S.，the European Union，Japan，and Canada [J ] . Onco-logist ， 2019 ， 24 （ 4 ）： 537 - 548 .

杜琼，叶璇，朱林蕙，等 . 抗肿瘤生物类似药临床转换应用及管理的专家共识 [J ] . 中国临床药学杂志， 2024 ， 33 （ 1 ）： 1 - 10 .

宋再伟，胡杨，余玲玲，等 . 中国生物类似药临床应用循证管理指南：2024 [J ] . 中国药房， 2024 ， 35 （ 16 ）： 1933 - 1945 .

LASALA R ， ABRATE P ， ZOVI A ， et al . Safety and effectiveness of multiple switching between originators and biosimilars：literature review and status report on interchangeability [J ] . Ther Innov Regul Sci ， 2023 ， 57 （ 2 ）： 352 - 364 .

GOLL G L ， JØRGENSEN K K ， SEXTON J ， et al . Long-term efficacy and safety of biosimilar infliximab（CT-P13）after switching from originator infliximab：open-label extension of the NOR-SWITCH trial [J ] . J Intern Med ， 2019 ， 285 （ 6 ）： 653 - 669 .

BERNARD E J ， FEDORAK R N ， JAIRATH V . Systema-tic review：non-medical switching of infliximab to CT-P13 in inflammatory bowel disease [J ] . Dig Dis Sci ， 2020 ， 65 （ 8 ）： 2354 - 2372 .

MENTER A ， COHEN S ， KAY J ， et al . Switching between adalimumab reference product and BI 695501 in patients with chronic plaque psoriasis（VOLTAIRE-X）：a rando-mized controlled trial [J ] . Am J Clin Dermatol ， 2022 ， 23 （ 5 ）： 719 - 728 .

NABI H ， HENDRICKS O ， JENSEN DV ， et al . Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease：clinical outcomes in real-world patients from the DANBIO registry [J ] . RMD Open ， 2022 ， 8 （ 2 ）： e002560 .

丁年羊，李莉，方攀奇，等 . 我院贝伐珠单抗生物类似药与原研药相关不良反应回顾性分析 [J ] . 中国药房， 2024 ， 35 （ 4 ）： 472 - 475 .

COHEN H P ， HACHAICHI S ， BODENMUELLER W ， et al . Switching from one biosimilar to another biosimilar of the same reference biologic：a systematic review of studies [J ] . BioDrugs ， 2022 ， 36 （ 5 ）： 625 - 637 .

COHEN H P ， BODENMUELLER W . Additional data in expanded patient populations and new indications support the practice of biosimilar-to-biosimilar switching [J ] . BioDrugs ， 2024 ， 38 （ 3 ）： 331 - 339 .

HERNDON T M ， AUSIN C ， BRAHME N N ， et al . Safety outcomes when switching between biosimilars and refer-ence biologics：a systematic review and meta-analysis [J ] . PLoS One ， 2023 ， 18 （ 10 ）： e0292231 .

HU Z C ， WU P ， SWANSON S J . Evaluating the immunogenicity risk of protein therapeutics by augmenting T cell epitope prediction with clinical factors [J ] . AAPS J ， 2025 ， 27 （ 1 ）： 33 .

PROCTOR J R ， WONG H . Time-dependent clearance can confound exposure-response analysis of therapeutic antibodies：a comprehensive review of the current literature [J ] . Clin Transl Sci ， 2024 ， 17 （ 1 ）： e13676 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

我国基本药物可获得性评价实证研究

基于WHO/HAI标准调查法的我国基本药物可及性评价方法研究

我国基本药物价格水平实证研究

我国基本药物可负担性评价实证研究

Related Author

管晓东信枭雄刘洋王天晟史录文

管晓东史录文

管晓东李晗刘洋史录文

管晓东信枭雄刘洋史录文

Related Institution

No data

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰